Chronic obstructive pulmonary diseases (COPD) is a pulmonary disease characterized by systemic abnormalities. The aim of this study is to investigate inflammation and systemic effects in mild COPD. Twenty-seven mild stable smoking related COPD patients and 15 age-matched healthy subjects were enrolled in the study. IL-6, TNF-a and IL-4 in plasma, sputum and exhaled breath condensate were measured. We also measured exhaled nitric oxide (NO) and pH in sputum and in breath condensate. Moreover, fat-free mass, body mass index (BMI), respiratory muscle strength, plasma oxidative stress and C-reactive protein (CRP) were measured. Higher concentrations were found of CRP, of diacron reactive oxygen metabolites (DROMs) and ofIL-6, TNF-a and IL-4 either in plasma or in supernatant of induced sputum or in exhaled breath condensate of COPD subjects compared to healthy controls. Furthermore, higher concentrations were observed of exhaled NO and lower exhaled pH in breath condensate of COPD when compared with healthy subjects. In the group of COPD patients, the subjects with airway reversibility showed an increase of sputum eosinophils and exhaled NO, whereas the subjects without airway obstruction reversibility showed an increase in sputum neutrophils, TNF-a and IL-6. We also found a trend towards a decrease in fat-free mass and respiratory muscle strength in COPD compared to healthy subjects and a negative correlation between these systemic indices (fatfree mass, maximal inspiratory pressure, maximal expiratory pressure) and TNF-a concentrations in the blood, sputum and breath condensate. We conclude that mild COPD subjects present an increase in inflammatory markers in blood and in airways of similar pattern and furthermore, the neutrophilic pattern of airway inflammation observed in the group of COPD subjects without an airway obstruction reversibility makes it more likely that systemic features are present.
These systemic effects may have an adverse effect on the quality of life and may contribute towards the mortality of COPD (6) (7) (8) . Systemic inflammation and oxidative stress appear to be risk factors for the majority of the systemic complications in COPD patients (9) . Several hypotheses have been suggested to explain how pulmonary inflammation and oxidative stress may spill over into the systemic circulation (10) (11) . There may be a genetic predisposition in some COPD subjects to develop both systemic and pulmonary inflammation (12) (13) . However, to date the exact mechanisms through which pulmonary inflammation and oxidative stress result in systemic effects in COPD remain unknown (2, 9) .
Moreover, increased reversibility to bronchodilators in COPD patients may share some of the features of asthma, such as eosinophilia (14) (15) (16) and increased exhaled nitric oxide (NO) (17) . Recently, our group demonstrated that COPD subjects with reversible obstruction present lower oxidative stress in airways (18) . These more reversible COPD patients may represent an intermediate group of patients between asthma and non-reversible COPO or may be COPD patients who also have concomitant asthma (19) .
The aim of this study is to investigate airway inflammation and systemic effects in mild COPD when compared with a group of healthy subjects. In particular we measured interleukin (IL)-6, tumor necrosis factor (TNF)-a and interleukin (IL)-4 in plasma, induced sputum and breath condensate, exhaled nitric oxide (NO), exhaled pH, inflammatory sputum cells and plasmatic C reactive protein (PCR) to investigate airway and sistemic inflammation and fat-free mass, body mass index (BMI), respiratory muscle strength, plasma oxidative stress to study the systemic effects of COPD.
MATERIALS AND METHODS

Study population
Twenty seven mild stable ex-smoker capo (52±4 yrs, 21 M, BASAL FEV\ 1.9±OAlt, 75.3±3.1% of predicted) and 15 healthy ex-smoker subjects (49±7 yrs, 12 M, BASAL FEV I 2.6±0.6 It, II OA±6.1 % of predicted) with no history of lung disease were studied (Table I ). The diagnosis of capo was based on ERS/ATS Guidelines (I). All subjects were recruited from the Respiratory Disease Institute, University of Foggia, and written informed consent was obtained from all subjects. The study was approved by the Institutional Ethics Committee.
None of the capo patients had a history of asthma or atopy or positive skin prick test, or were suffering from chronic congestive heart failure. All patients were in a stable condition at the time of the study and free from acute exacerbations of symptoms or upper respiratory tract infections in the 3 months preceding the study.
Only mild capo were selected to avoid the influence on systemic effects of overlapped conditions that often appear in advanced stages of capo (cardiovasura disorders, respiratory failure and others).
Healthy subjects had no respiratory symptoms and no respiratory tract infection for~3 months prior to the study. All capo patients and healthy subjects enrolled were ex-smokers from at least 6 months preceding the study. capo patients were enrolled during routine hospital visits. A full medical history was taken and general physical examination was performed. Patients then underwent lung function testing, skin prick test for common inhalant allergens, serum total IgE, arterial blood gas analysis, laboratory tests, fat-free mass, maximal inspiratory pressure (PImax), maximum expiratory pressure (PEmax), exhaled NO measurement, blood and breath condensate and induced sputum collection. None of patients included was treated with oral steroids and only short-acting inhaled~2-agonists were allowed for symptom relief.
Study design
On the first day subjects underwent clinical data collection, physical analysis, lung function, fat free mass and respiratory muscle strength measurements and blood tests.
On the second day exhaled NO, exhaled breath condensate collection and sputum induction were performed.
Pulmonary function testing and assessment ofairflow limitation
Pulmonary function tests were performed prior to the measurement of exhaled breath condensate. FEV " FVC and FEV/FVC ratio were measured using a dry spirometer (Vmax Spectra series, SensorMedics Corporation, Yorba Linda, California, USA). The highest value of three manoeuvres was expressed as a percentage of the predicted normal value. Reversible airflow limitation were defined as an increase in FEV 1 of>200 ml and/or~12% from baseline 30 min after inhalation of200 ug of salbutamol (I).
Fat-free mass measurement
Fat-free mass was determined by bioelectric impedance analysis (Bodystat 1500; Douglas, UK) (20) .
Respiratory muscle strength
Respiratory muscle strength was assessed by measurement of mouth pressure at maximal static inspiratory and espiratory efforts from residual volume and total lung capacity, PImax (maximal inspiratory pressure) and PEmax (maximal expiratory pressure) against an obstructed mouthpiece with a small leak to minimize oral pressure artifacts (Spirovis, Cosmed S.R.L., Italy) (21) .
Induced sputum
Sputum was collected and processed according to the method of Spanevello et al (22) . All sputum counts and measurements were performed blind to the clinical details. Definition of an adequate selected sputum was one in which there were fewer than 20% squamous cells and viability> 50%. A specific enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, USA) was used to measure TNF-a and IL-6 concentrations in supernatant of induced sputum.
Exhaled breath condensate and assay
Exhaled breath condensate (EBC) was collected by using the EcoScreen, (Jaeger, Wurzburg, Germany). The subjects breathed through a mouthpiece and a two-way non-rebreathing valve, which also served as a saliva trap. They were asked to breathe at a normal frequency and tidal volume, wearing a nose clip, for a period of 10 min. Ifsubjects felt saliva in their mouth they were instructed to swallow it. Condensate, at least 1 ml, was collected as ice at -20°C, transferred to Eppendorftubes and immediately stored at -70°C. Samples were analysed within 3 months from collection. To exclude saliva contamination amylase activity was analysed in EBC.
Measurement ofexhaled NO
A rapid-response chemiluminescence NO analyzer (model 280; Sievers Instruments; Boulder, Colorado, USA) was used to quantify NO. Two-point calibrations were performed daily using 5.2-parts per million calibration gas. Exhaled NO (FENO) was measured using a previously described restricted breathing technique, which employed expiratory resistance and positive mouth pressure to close the velum and exclude nasal NO, and a constant expiratory flow of 45 mUs. The inhaled gas was ambient air that was passed through a filter to reduce inhaled NO concentrations to <5 parts per billion (ppb). Subjects inhaled to total lung capacity, and exhaled while targeting a constant pressure of 20 mm Hg. Exhalations proceeded until a clear NO plateau of at least 3s duration was achieved. Repeated exhalations were performed until three plateaus agreed within 5% (23) .
IL-6, TNF-a and IL-4 measurements
A specific enzyme immunoassay kit (Cayman Chemical, Ann Arbor, Michigan, USA) was used to measure IL-6, TNF-a and IL-4 concentrations in plasma, supernatant of induced sputum and breath condensate. The intra-assay and inter-assay variability were ::;10% for each assay and the detection limit of the assays was 1.5 pg/ml, 4 pg/ml and 20 pg/ml, respectively. The coefficient of variation for IL-6, TNF-a, IL-4 and pH were 5.9%; 3,3%; 4.2% and 0.4% respectively. Reproducibility of exhaled IL-6, TNF-a and pH measurements were assessed in l Onon-smoking normal subjects.
pH measurements
A stable pH was achieved in all cases after deaeration! decarbonation of supernatant of induced sputum and breath condensate specimens by bubbling with argon (350 ml/min) for 10 min, as previously described (24) . pH was then measured within 5 minutes ofcondensate collection by means of a pH meter (Jenway-350, Ltd Gransmore Green, UK) with a 2 to 16.00 pH range and a resolution! accuracy on the order of 0.01 ± 0.02 pH.
Plasma reactive oxygen metabolites measurement
Systemic oxidative stress was measured by the diacron reactive oxygen metabolites (D-ROM) test (Diacron International, Italy) (25) . Values of DROMS were expressed as Carratelli Units, where 1 U.CARR corresponds to 0.8 mg/L HP2' Plasma CRP measurement Plasma CRP was measured using the N high sensitivity CRP Kit (Dade Berhing, Marburg, Germany) which has a lower limit of detection of 0.15 mg/L.
Statistical analysis
Data are expressed as means±SD. A Mann-Whitney test was used to compare groups, and correlations between variables were performed using Spearman's rank correlation test. Significance was defined as a p value of <0.05.
RESULTS
Lungfunction
All COPD were defined as mild according to GOLD guidelines (26) . COPD subjects showed lower percentages of FEV\ and FEV/FVC ratio compared to healthy controls (82.6±1. 5 .. ( 
Sputum measurements
Sputum induction was performed in all subjects without observing any significant adverse effect or a decrease in FEV, >20%. Four healthy subjects and 6 capo patients did not produce adequate sputum samples, and their expectorates were discarded. Table II and Fig. 1 show the comparison between the three groups in term of percentage of cells found in the induced sputum. Higher percentages were found of neutrophils and eosinophils and a reduction of macrophages in Lower values of pH were found in non-reversible compared to reversible capo (7.48±0.07 vs 7.52±0.05).
Exhaled breath condensate measurements
Elevated concentrations of IL-6 (8.30±1.94 vs 4.18±0.63 pglml), TNF-a (9.53±2.35 vs 5.65±0.99 pg/ml), IL-4 (55.15±7.88 vs 34.83±5.79 pg/ml) and a lower pH (7.46±0.08 vs 7.68±0.23) were found in exhaled breath condensate of capo subjects compared to healthy controls (Table I) .
Higher concentrations of IL-6 (9.49±2.55 vs 7.08±1.07 pg/ml) and TNF-a (11.51±2.60 vs 7.72±0.68 pglml) and lower concentrations of IL-4 (49.49±5.56 vs 60.07±8.13 pg/ml) were observed in exhaled breath condensate of nonreversible compared to reversible capo (Fig. 2-4 ).
Lower levels of pH were found in exhaled breath condensate of reversible compared to non-reversible Reversible COPD vs non-reversible COPD: *p <0.05; **p <0.01 COPO (7.43±0.07 vs 7.49±0.06) ( Fig. 2-4 ). Elevated concentrations of exhaled NO were observed in COPO patients compared to control subjects (24.97±7.94 vs 9.07±1.64 ppb) and in reversible compared to non-reversible COPO (29.59±6.41 vs 20.3±8.9 ppb) (Table I and Fig. 5 ). (Table I) . COPO patients also showed higher concentrations of white blood cells (7.9±1.9 vs 5.1±1.3 xl0 9/1), blood eosinophils (0.41±0.26 vs 0.23±0.15 x 10 9/1) and CRP (l1.55±11.11 vs 0.7±0.9 mg/l) than healthy subjects. We also observed a reduction of BMI (21.0±2.4 vs 24.5±2.6 kg/m-) between COPO patients and control subjects, although this did not achieve significance.
Systemic measurements
Plasma concentrations
Higher concentrations of OROMs (267.8±34.12 vs 36.8±6.0 U.CARR), IL-6 (9.18±2.31 vs 5.82±0.89 pg/ml), TNF-a (11.22±3.67 vs 6.06±1.55 pg/ml) and IL-4 (72.43±10.43 vs 38.71±5.33 pg/ml) were found in plasma of COPO patients compared with healthy subjects (Table I) .
The plasma levels ofIL-6 and TNF-a were higher in non-reversible COPO (l0.72±2.72 vs 7.57±1.52 pg/ml and 13.57±4.49 vs 8.66±1.29 pg/ml) whereas the levels of IL-4 were higher in reversible COPO (78.66± I0.22 vs 65. 72± I0.03 pg/ml) when compared to healthy subjects (Fig. 2-4 ).
Correlations
The relations between the fat-free mass with the inflammatory markers were studied using the Spearman's rank correlation test, finding negative correlations between fat-free mass and TNF-a in plasma (p<O.OOI, r=-0.83), TNF-a in supernatant of induced sputum (p<O.OOl, r=-0.75), TNF-a in breath condensate (p<0.05, r=-0.44) and between PImax, PEmax and TNF-a in plasma (p<O.OI, r=-0.61; p<O.Ol, r=-0.64), TNF-a in supernatant of induced sputum (p<0.05, r=-0.50; p<0.05, r=-0.48), TNF-a in breath condensate (p<0.05, r=-0.53; p<0.05, r=-0.46). Furthermore, a strong correlation was observed between PImax and fat-free mass (p<O.OI, r=0.67).
DISCUSSION
Several recent studies have investigated the inflammation in COPO and the possible mechanisms of its systemic effects (2) (3) (4) (5) . In agreement with previous studies we found significant increases in several inflammatory biomarkers (CRP, TNFu, IL-6) (9, 27-37) and leukocytes (9, 27) in the peripheral blood of a group of ex-smoker COPO patients compared to age-matched healthy subjects. Moreover, we also measured the same inflammatory markers in the supernatant of the induced sputum and in breath condensate in order to compare with the pattern of pulmonary inflammation, and an increase was found in the concentrations of the same inflammatory markers in capo patients compared to healthy subjects, indicating that in capo patients pulmonary and systemic inflammation has a similar pattern (32) .
Previous studies have characterized the pulmonary inflammation in capo patients by measuring cells in induced sputum, and have shown an increase in eosinophils in reversible capo compared to an increase ofneutrophils in non-reversible capo (17) . We have confirmed these differences in our own study. We also found higher levels ofIL-6 and TNFa in plasma, in supernatant of the induced sputum and in breath condensate of non-reversible capo, whereas we found higher levels of IL-4, which is usually associated with allergic inflammation, in patients with reversible capo. This is the first time that IL-4 has been detected in supernatant of induced sputum and in breath condensate of capo subjects. We also found higher levels of exhaled NO in capo patients with reversible airflow limitation, in agreement with a previous study (17) .
We also measured pH of the breath condensate and found lower values in COPD patients compared with healthy subjects, in agreement with a previous study (33) . We also found a similar reduction in pH values in supernatant of induced sputum confirming acidification of the lower airways in capo patients. No differences in pH were found between reversible capo and non-reversible capo, suggesting that both eosinophilic and neutrophilic inflammation could cause a decrease of pH.
Several studies have highlighted nutritional abnormalities in capo patients, including alterations in caloric intake, basal metabolic rate, intermediate metabolism and body composition (34) (35) . Moreover, alterations in body composition may occur in capo in the absence of clinically significant weight-loss (36) . In our study we found a decrease in fat-free mass in capo patients compared with healthy subjects. We also found a lower fat-free mass in non-reversible capo than in reversible capo, although this difference did not achieve statistical significance. We investigated a possible relation between fat-free mass and inflammatory markers and found no correlation with IL-6 and IL-4, but a strong negative correlation between fat-free mass and TNF-a in plasma, sputum supernatant and in breath condensate. Previous reports have highlighted the potential role of TNF-a in inducing catabolic responses in tissues, triggering muscle proteolysis and increased protein degradation (37) . Our findings suggest that there could be a relation between inflammation (local and/or systemic) and body composition in capo patients and this relation, because of its significant correlation with TNF-a, a mediator associated with neutrophilic inflammation, could be more important in non-reversible capo patients. We found a similar trend in the values of PImax and PEmax: which were lower in non-reversible capo (although this did not achieve significance) and there was a negative correlation between these measurements of muscle strength with TNF-a concentrations in plasma. This is not surprising as a decrease of fat-free mass can cause a decrease of the muscular strength and so a decrease in the values of the PImax and PEmax (6) . Indeed, we confirmed a strong correlation between . PImax and fat-free mass. The involvement ofTNFa in the weight loss of capo has already been investigated, while the other markers (CRP, IL-6) are more associated with cardiovascular complications (37) (38) (39) .
Finally, we have confirmed a link between inflammation and oxidative stress, which may reflect increased transcription pro-inflammatory cytokine genes in response to reactive oxygen species (39) . In capo there is increased oxidative stress in exhaled breath and in plasma (40) . In a previous study we described an increase of oxidative stress and oxidative protein damage in induced sputum of non-reversible capo compared to reversible (18) . In this study we found an increase of the value of plasma DRaMs among the capo patients, particularly among the non-reversible capo patients, that is in line with our previous data on airways of non-reversible capo and proved the presence of a concomitant systemic oxidative stress in these patients.
capo is characterized by an intense inflammatory process in the airways, parenchyma and pulmonary vasculature, and this process may spill over into the systemic circulation, promoting a generalised inflammatory reaction (31) . Our study confirms previous studies of local and systemic inflammation in COPD patients, and distinguishes patterns of inflammation between reversible and non-reversible COPD. The similarity between the pattern and pulmonary inflammation (measured by induced sputum and exhaled breath condensate) and systemic markers of inflammation adds support to the idea that systemic effects arise from a spillover of inflammation from the lung. Furthermore, these systemic features more closely mimic the neutrophilic pattern of inflammation associated with non-reversible COPD, indicating that this form of COPD is more likely to be associated with systemic effects.
